The drug eluting balloon (DEB) has demonstrated safety and efficacy for treatment of restenosed and de novo lesions in coronary artery disease in several clinical trials. Late lumen loss at follow-up is consistently low (~0.2mm), and no thrombotic event has been reported when using the DEB (Sequent®Please) as a stand-alone therapy.
Some issues remain when combining the DEB with a bare metal stent (BMS), since geographic mismatch (DEB does not cover total stented area) between DEB and BMS can not always be avoided. The combination of the DEB with a BMS further results in a somewhat ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com